Mashup Score:35
Nature# ASH22
Mashup Score:9
American Society of HematologyHematology | American Society of Hematology - 1 week
Mashup Score:9
Skip Nav Destination Current Issue Volume 2022, Issue 1, December 9 2022...
-
From basic discovery & disease pathogenesis to the clinical application at the bedside, the Hematology 2022 ASH Education Program covers it all! Read more on each #ASH22 education session now: https://t.co/tTUVPzouXL https://t.co/tTUVPzouXL - view on twitter
More coverage:
#ash22
Mashup Score:8
multiplemyelomahub.comInitial results of daratumumab + lenalidomide in frail patients: The IFM 2017-03 trial - 1 week
Mashup Score:8
The Multiple Myeloma Hub summarizes data from the IFM 2017-03 trial, presented at ASH 2022, exploring the efficacy and safety of dexamethasone alongside lenalidomide...
-
#ASH22 | Want to know more about the efficacy and safety of daratumumab and lenalidomide, without dexamethasone, for the treatment of NDMM in frail patients? Read more about the IFM 2017-03 clinical trial here. 👉 https://t.co/nNFOwZKzjW #mmsm #myeloma https://t.co/nNFOwZKzjW - view on twitter
Mashup Score:6
VJHemOncRashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of novel technologies...
-
We spoke to @kanagalshamanna (@MDAndersonNews) at #ASH22, who shared insights into the use of optical genome mapping for characterization of chromoanagenesis and TP53 mutations in MDS patients: 👉 https://t.co/BqaQKenPvl 👈 @ASH_hematology #HemOnc #MDSsm - view on twitter
Mashup Score:5
Blood Cancers TodayAssessing Optimal Combinations for Treatment of Lymphoma | Blood Cancers Today - 1 week
Mashup Score:5
The panel discusses combination therapy options for patients with DLBCL and...
-
What are the optimal treatment combinations for DLBCL and follicular lymphoma? @kmaddmd of @OSUCCC_James; Pierluigi Porcu, MD, of @KimmelCancerCtr; @PamAllenMD1 of @WinshipAtEmory; and @DrJFriedberg of @WilmotCancer, weighed in during #ASH22. https://t.co/sjhzNJjdJl - view on twitter
More coverage:
#ash22
Mashup Score:5
VJHemOncAshutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on patient...
-
Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh: 🎥: https://t.co/MNxW6m0RK3 #ASH22 #Amyloidosis #BMTsm #HemOnc - view on twitter
Mashup Score:5
lymphomahub.comNovel combinations for the frontline treatment of patients with DLBCL - 2 days
Mashup Score:5
Results from two presentations at the 64th American Society of Hematology (ASH) Annual Meeting oral abstracts session reported key data around novel combinations for...
-
Promising outcomes of novel frontline treatment combinations (bortezomib+R-CHOP and glofitamab+R-CHOP) in patients with DLBCL were presented at the oral abstract session of #ASH22. Check out our summary here 👉 https://t.co/yfdA55GIEV. #lymsm https://t.co/yfdA55GIEV. - view on twitter
Mashup Score:4
Blood Cancers TodayThe panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma...
-
What are the regulatory hurdles and access considerations for non-Hodgkin lymphoma therapies? @kmaddmd of @OSUCCC_James ; Pierluigi Porcu, MD, of @KimmelCancerCtr; @PamAllenMD1 of @WinshipAtEmory; and @DrJFriedberg of @WilmotCancer, discuss during #ASH22. https://t.co/xE03b9L6WD - view on twitter
More coverage:
#ash22
Mashup Score:4
American Society of HematologyHighlights of ASH in Latin America - 5 days
Mashup Score:4
April 28-29, 2023 São Paulo, Brazil Join the world’s leading hematology experts at Highlights of ASH in Latin America, a two-day program that highlights...
-
Acompáñenos en São Paulo para Highlights of ASH en América Latina y forme conexiones con profesionales de #hematología en la región 🌍🥼 Regístrese hoy para un resumen de la ciencia más destacada de #ASH22: https://t.co/VE3FjVhtgn https://t.co/VE3FjVhtgn - view on twitter
Mashup Score:4
Blood Cancers TodayA new method to detect minimal residual disease (MRD) in peripheral blood had an “unprecedented sensitivity” level of 10−8 in samples from patients with...
-
A new MRD detection method showed “unprecedented sensitivity” in peripheral blood samples from patients with multiple myeloma, according to research presented during #ASH22 by Laura Notarfranchi, MD, of @unipr, and colleagues. @SocietyofHemOnc https://t.co/VDwxjg6I9c - view on twitter
More coverage:
#ash22
Bone Marrow Transplantation – Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T...
It was great to talk to @Keira_i3Health #OncData on CAR-T wait list in multiple myeloma #mmsm #ASH22 @UAMSMyeloma @uamscancer Link to the published paper: https://t.co/KJi1IagPgV https://t.co/KJi1IagPgV - view on twitter